Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-Current Debt (2019 - 2025)

Tg Therapeutics (TGTX) has 7 years of Non-Current Debt data on record, last reported at $245.6 million in Q4 2025.

  • For Q4 2025, Non-Current Debt changed 0.5% year-over-year to $245.6 million; the TTM value through Dec 2025 reached $245.6 million, changed 0.5%, while the annual FY2025 figure was $245.6 million, 0.5% changed from the prior year.
  • Non-Current Debt reached $245.6 million in Q4 2025 per TGTX's latest filing, roughly flat from $245.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $245.6 million in Q4 2025 and bottomed at $66.8 million in Q4 2021.
  • Average Non-Current Debt over 5 years is $141.9 million, with a median of $100.1 million recorded in 2023.
  • Peak YoY movement for Non-Current Debt: soared 765.58% in 2021, then rose 0.48% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $66.8 million in 2021, then grew by 6.51% to $71.1 million in 2022, then skyrocketed by 40.74% to $100.1 million in 2023, then skyrocketed by 144.14% to $244.4 million in 2024, then rose by 0.5% to $245.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $245.6 million in Q4 2025, $245.3 million in Q3 2025, and $245.0 million in Q2 2025.